J&J's Symtuza Will Debut In Europe On Cramped HIV Market
Johnson & Johnson's combination HIV therapy Symtuza has secured a greenlight in Europe, marking its first approval worldwide – but will the big pharma be able to catch up with successful HIV opponents from AbbVie and Gilead?
You may also be interested in...
The first HIV single-tablet regimen anchored by a protease inhibitor, Symtuza’s prospects are challenged by competitors already on the market and treatment guidelines that prefer integrase inhibitor regimens.
ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research.
Switching to a once-daily single tablet containing four constituents that is centered on Janssen's protease inhibitor darunavir was non-inferior to other combination therapies after 48 weeks of therapy, say researchers running the Phase III EMERALD study.